Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
166.08
-4.95 (-2.89%)
After Hours: 166.08 0.00 (0.00%)
Jul 28, 6:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 164.18 - 171.71
52 week 72.77 - 185.00
Open 171.09
Vol / Avg. 0.00/1.30M
Mkt cap 21.32B
P/E 115.39
Div/yield     -
EPS 1.44
Shares 128.40M
Beta 0.55
Inst. own 110%
Oct 20, 2014
Q3 2014 Illumina Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 23, 2014
Q2 2014 Illumina Inc Earnings Call - Webcast
Jul 23, 2014
Q2 2014 Illumina, Inc. Earnings Release
Jun 11, 2014
Illumina, Inc. at Goldman Sachs Healthcare Conference - Webcast
Jun 3, 2014
Illumina, Inc. at Bank of America Merrill Lynch Global Technology Conference - Webcast
May 28, 2014
Illumina, Inc. Annual Shareholder Meeting - Webcast
May 13, 2014
Illumina, Inc. at Bank of America Merrill Lynch Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 10.41% 8.82%
Operating margin 22.40% 9.44%
EBITD margin - 24.77%
Return on average assets 6.14% 4.49%
Return on average equity 14.09% 8.79%
Employees 3,000 -
CDP Score - -

Address

5200 Illumina Way
SAN DIEGO, CA 92122
United States - Map
+1-858-2024500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies. In July 2014, the Company acquired Myraqa, a regulatory and quality consulting firm specializing in IVDs, particularly companion diagnostics.

Officers and directors

William H. Rastetter Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Francis A. deSouza President, Director
Age: 43
Bio & Compensation  - Reuters
Jay T. Flatley Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marc A. Stapley Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
David R. Walt Ph.D. Chairman - Scientific Advisory Board, Independent Director
Age: 61
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Christian O. Henry Senior Vice President, Chief Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Nicholas J. Naclerio Ph.D. Senior Vice President, Corporate Development & General Manager - Enterprise Informatics
Age: 41
Bio & Compensation  - Reuters
Tina S. Nova Ph.D. Senior Vice President, General Manager - Oncology
Age: 60
Bio & Compensation  - Reuters